These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 18646147)

  • 1. Intermediate acting versus long acting insulin for type 1 diabetes mellitus.
    Vardi M; Jacobson E; Nini A; Bitterman H
    Cochrane Database Syst Rev; 2008 Jul; 2008(3):CD006297. PubMed ID: 18646147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.
    Siebenhofer A; Plank J; Berghold A; Narath M; Gfrerer R; Pieber TR
    Cochrane Database Syst Rev; 2004; (2):CD003287. PubMed ID: 15106199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.
    Siebenhofer A; Plank J; Berghold A; Narath M; Gfrerer R; Pieber TR
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003287. PubMed ID: 15495047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.
    Fullerton B; Siebenhofer A; Jeitler K; Horvath K; Semlitsch T; Berghold A; Plank J; Pieber TR; Gerlach FM
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD012161. PubMed ID: 27362975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus.
    Fullerton B; Siebenhofer A; Jeitler K; Horvath K; Semlitsch T; Berghold A; Gerlach FM
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD013228. PubMed ID: 30556900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.
    Siebenhofer A; Plank J; Berghold A; Jeitler K; Horvath K; Narath M; Gfrerer R; Pieber TR
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003287. PubMed ID: 16625575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
    Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis.
    Szypowska A; Golicki D; Groele L; Pańkowska E
    Pol Arch Med Wewn; 2011; 121(7-8):237-46. PubMed ID: 21878861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WITHDRAWN: Inhaled insulin in diabetes mellitus.
    Royle P; Waugh N; Deakin M; Philip S
    Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD003890. PubMed ID: 19160227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
    Monami M; Marchionni N; Mannucci E
    Diabetes Obes Metab; 2009 Apr; 11(4):372-8. PubMed ID: 19267715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
    Rys P; Wojciechowski P; Siejka S; Małecki P; Hak L; Malecki MT
    Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled insulin in diabetes mellitus.
    Royle P; Waugh N; McAuley L; McIntyre L; Thomas S
    Cochrane Database Syst Rev; 2004; (3):CD003890. PubMed ID: 15266506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and complications of long-acting and intermediate-acting insulin regimens for adults with type 1 diabetes: an individual patient data network meta-analysis.
    Veroniki AA; Seitidis G; Stewart L; Clarke M; Tudur-Smith C; Mavridis D; Yu CH; Moja L; Straus SE; Tricco AC
    BMJ Open; 2022 Nov; 12(11):e058034. PubMed ID: 36332950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled insulin in diabetes mellitus.
    Royle P; Waugh N; McAuley L; McIntyre L; Thomas S
    Cochrane Database Syst Rev; 2003; (3):CD003890. PubMed ID: 12917994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, effectiveness, and cost of long-acting versus intermediate-acting insulin for type 1 diabetes: protocol for a systematic review and network meta-analysis.
    Tricco AC; Ashoor HM; Soobiah C; Hemmelgarn B; Moher D; Hutton B; Yu CH; Majumdar SR; Straus SE
    Syst Rev; 2013 Sep; 2():73. PubMed ID: 24020869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C
    Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
    Heller S; Buse J; Fisher M; Garg S; Marre M; Merker L; Renard E; Russell-Jones D; Philotheou A; Francisco AM; Pei H; Bode B;
    Lancet; 2012 Apr; 379(9825):1489-97. PubMed ID: 22521071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.